Phase 2
Xilio Therapeutics Stock Plunges Following Initial Phase 2 Data for Vilastobart in Colorectal Cancer Treatment
Xilio Therapeutics, Vilastobart, Anti-CTLA-4, Colorectal Cancer, Stock Price, Phase 2 Data
Cardiff Oncology’s Onvansertib Shows Promising Results in First-Line RAS-Mutated Metastatic Colorectal Cancer Trial
Cardiff Oncology, Onvansertib, RAS-mutated metastatic colorectal cancer, Phase 2 CRDF-004 trial, objective response rate (ORR), first-line treatment.
Protara’s TARA-002 Cell Therapy Shows Exceptional Promise in Treating Non-Muscle Invasive Bladder Cancer
Protara Therapeutics, TARA-002, Non-Muscle Invasive Bladder Cancer (NMIBC), Phase 2 ADVANCED-2 trial, Cell therapy, BCG-Unresponsive, BCG-Naïve
Boston Pharmaceuticals Achieves Phase 2 Success with Efimosfermin Alfa for MASH Treatment, Paving Way for Pivotal Trials
Efimosfermin alfa (BOS-580), Metabolic dysfunction-associated steatohepatitis (MASH), Non-alcoholic steatohepatitis (NASH), Phase 2 clinical trials, FGF21 analogue, Liver disease treatment, Pivotal trials
Neurocrine Biosciences Advances Schizophrenia Treatment with Positive Phase 2 Data for NBI-1117568
Neurocrine Biosciences, schizophrenia, NBI-1117568, Phase 2 data, Phase 3 advancement, muscarinic M4 selective acetylcholine receptor agonist
GSK Abandons Phase 2 HPV Vaccine Due to Lack of Best-in-Class Potential
GSK, HPV vaccine, phase 2, best-in-class potential, vaccine development
Huntington’s Disease Clinical Trials: Updates on Dalzanemdor and Tominersen
Huntington’s disease, clinical trials, dalzanemdor, tominersen, cognitive impairment, RNA-based therapy, NMDA receptor modulator, Phase 2 and Phase 3 studies
Oculis Announces Phase 2 Results for Licaminlimab in Dry Eye Disease, Despite Limited Statistical Significance
Oculis, Licaminlimab, Dry Eye Disease, Phase 2 Results, Statistical Significance